Article Details
Retrieved on: 2021-06-28 16:41:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
RedHill Biopharma presented positive Phase II safety and efficacy data for Yeliva (oral opaganib) in hospitalized patients with COVID-19 pneumonia.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here